ARJO-B 📈 Arjo AB (publ) - Overview

Exchange: ST • Country: Sweden • Currency: SEK • Type: Common Stock • ISIN: SE0010468116

ARJO-B: Medical Devices, Beds, Hygiene Products, Diagnostic Equipment

Arjo AB (publ) is a leading developer and supplier of medical devices and solutions, primarily focused on improving clinical and financial outcomes for healthcare institutions across the globe. With a presence in Europe, Asia and Pacific, South America, Africa, and other international markets, the company offers a comprehensive range of products and solutions tailored to specific patient needs. These include patient handling and hygiene systems, medical beds, pressure injury prevention and management solutions, as well as diagnostics and treatment options for conditions such as deep vein thrombosis, edema, and leg ulcers.

The company's product portfolio also encompasses obstetric and cardiac diagnostics, providing healthcare professionals with the necessary tools to deliver high-quality care. Furthermore, Arjo AB (publ) offers specialized solutions for dementia and bariatric care, including room assessments and equipment designed to support early mobility and rehabilitation. Additional services include maintenance, equipment rental, and financing solutions, all aimed at supporting the operational efficiency and financial sustainability of healthcare institutions. By catering to both private and public healthcare providers, the company plays a vital role in the delivery of acute and long-term care services.

With a history dating back to 1957, Arjo AB (publ) has established itself as a trusted partner in the healthcare sector, leveraging its expertise and experience to drive innovation and improvement in patient care. Headquartered in Malmö, Sweden, the company is committed to delivering value to its customers, shareholders, and the broader healthcare community. As a publicly traded company, Arjo AB (publ) is listed under the ISIN code SE0010468116, classified as a common stock, and operates within the Health Care Distributors sub-industry. For more information, please visit the company's website at https://www.arjo.com/int/.

Additional Sources for ARJO-B Stock

Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle

ARJO-B Stock Overview

Market Cap in USD 880m
Sector Healthcare
Industry Medical Distribution
GiC Sub-Industry Health Care Distributors
IPO / Inception

ARJO-B Stock Ratings

Growth 5y -38.2%
Fundamental 50.6%
Dividend 38.5%
Rel. Strength Industry -634
Analysts -
Fair Price Momentum 32.67 SEK
Fair Price DCF 113.71 SEK

ARJO-B Dividends

Dividend Yield 12m 2.51%
Yield on Cost 5y 2.10%
Annual Growth 5y -7.09%
Payout Consistency 92.0%

ARJO-B Growth Ratios

Growth Correlation 3m -25.6%
Growth Correlation 12m -81.9%
Growth Correlation 5y -58%
CAGR 5y -3.08%
CAGR/Mean DD 5y -0.08
Sharpe Ratio 12m -0.38
Alpha -22.42
Beta 0.32
Volatility 33.14%
Current Volume 2119k
Average Volume 20d 550.7k
What is the price of ARJO-B stocks?
As of January 15, 2025, the stock is trading at SEK 37.00 with a total of 2,118,954 shares traded.
Over the past week, the price has changed by -2.18%, over one month by +5.97%, over three months by -14.94% and over the past year by -15.38%.
Is Arjo AB (publ) a good stock to buy?
Partly, yes. Based on ValueRay Fundamental Analyses, Arjo AB (publ) (ST:ARJO-B) is currently (January 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 50.55 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ARJO-B as of January 2025 is 32.67. This means that ARJO-B is currently overvalued and has a potential downside of -11.7%.
Is ARJO-B a buy, sell or hold?
Arjo AB (publ) has no consensus analysts rating.
What are the forecast for ARJO-B stock price target?
According to ValueRays Forecast Model, ARJO-B Arjo AB (publ) will be worth about 35.3 in January 2026. The stock is currently trading at 37.00. This means that the stock has a potential downside of -4.62%.
Issuer Forecast Upside
Wallstreet Target Price 41 10.8%
Analysts Target Price - -
ValueRay Target Price 35.3 -4.6%